title: Avastin and Lucentis: what do patients know? A prospective questionnaire survey.
abstract: OBJECTIVE
  To assess patients' knowledge of their drug therapy for neovascular macular degeneration and to identify which aspects of the drug they considered most important if given the option of switching to an alternative drug.
  
  
  METHODS
  Prospective questionnaire survey.
  
  
  METHODS
  Wolverhampton, England.
  
  
  METHODS
  A total of 126 patients attending our hospital service for intravitreal ranibizumab therapy for neovascular macular degeneration.
  
  
  METHODS
  Using a questionnaire, patients were asked questions pertaining to aspects of drug therapy in neovascular macular degeneration. Fields covered included drug names, knowledge of alternative drugs, cost of drugs and their views on switching to another drug.
  
  
  RESULTS
  Eighty (63.5%) had heard of Lucentis (ranibizumab) and 31 (24.6%) were aware of Avastin (bevacizumab). Of the latter 31 patients, 20 did not have a preference between Avastin and Lucentis. These patients felt that the factors they would consider important for them to consider switching were effectiveness (10, 50%), specialist recommendation (8, 40%), safety (2, 10%) and cost (0).
  
  
  CONCLUSIONS
  Introducing a cheaper, off-label alternative in the therapy of macular degeneration in the presence of a licensed option has been extensively debated. Many patients have no knowledge of this controversial issue but it is likely that efficacy and recommendation by clinicians are more important than cost to patients who may consider switching to the off-label Avastin.
authors.affiliation: Wolverhampton Eye Infirmary, The Royal Wolverhampton Hospitals NHS Trust, Wolverhampton WV10 0QP, UK.
authors.forename: Avinash
authors.initials: A
authors.lastname: Manna
authors.forename: Oluwatoyin
authors.initials: O
authors.lastname: Oyede
authors.forename: Brigid
authors.initials: B
authors.lastname: Ning
authors.forename: Yit
authors.initials: Y
authors.lastname: Yang
authors.forename: Niro
authors.initials: N
authors.lastname: Narendran
references.citation: Nature. 1993 Apr 29;362(6423):841-4
references.pmid: 7683111
references.citation: Ophthalmology. 2012 Jul;119(7):1388-98
references.pmid: 22555112
references.citation: BMC Public Health. 2006 Mar 08;6:58
references.pmid: 16524463
references.citation: Retina. 2011 Apr;31(4):662-8
references.pmid: 21836400
references.citation: Ophthalmology. 2011 Jun;118(6):1089-97
references.pmid: 21640257
references.citation: Eye (Lond). 2011 Dec;25(12):1617-21
references.pmid: 21921947
references.citation: Eye (Lond). 2010 Feb;24(2):226-32
references.pmid: 19407833
references.citation: Br J Ophthalmol. 2011 Oct;95(10):1433-6
references.pmid: 21317425
references.citation: Ophthalmology. 2012 Jul;119(7):1399-411
references.pmid: 22578446
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Am J Ophthalmol. 2011 Oct;152(4):509-14
references.pmid: 21961847
references.citation: Ophthalmology. 2009 Jan;116(1):57-65.e5
references.pmid: 19118696
references.citation: Am J Ophthalmol. 2012 Feb;153(2):204-208.e1
references.pmid: 22264943